Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Recruiting

Study of drug combination (capecitabine, fluorouracil, oxaliplatin, calcium folinate) to prevent cancer recurrence in patients with detectable ctDNA after rectal cancer surgery

Verified siteRegistered drugNo placebo
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

What is this trial about?

A plain-language summary of the goals, design and what participants do

This clinical trial focuses on patients with rectal cancer who show signs of tumor DNA in their blood after surgery. The study aims to determine if additional treatment after surgery can help prevent the cancer from returning. The treatment being studied combines several anti-cancer medications: capecitabine (taken by mouth), fluorouracil and oxaliplatin (given through a vein), along with calcium folinate which helps enhance the effectiveness of fluorouracil.

The treatment involves a combination of medications commonly used to treat cancer, known as chemotherapy. These drugs work together to destroy any remaining cancer cells that might be present in the body after surgery. The treatment will be given over several months to determine if it can improve the time patients remain free from cancer returning.

During the study, patients will receive the chemotherapy treatment and have regular check-ups to monitor their health. Blood samples will be taken to check for signs of cancer DNA, which can indicate whether the treatment is working. The study will track how long patients remain cancer-free and their overall survival, while also monitoring their quality of life during and after treatment.

The research process

The trial runs in 5 steps – from screening to follow-up. Each step says what happens and what the team monitors.

  1. Step 1

    Initial screening and confirmation

    Your eligibility for the study will be verified based on specific criteria, including being at least 18 years old and having a WHO performance score of 0-1

    Confirmation of rectal cancer diagnosis through histological examination is required

    A blood test will be performed to check for detectable ctDNA (circulating tumor DNA) in your post-surgery blood sample

  2. Step 2

    Treatment assignment

    You will be assigned to receive adjuvant chemotherapy treatment

    The treatment will consist of either CAPOX or FOLFOX chemotherapy regimen

  3. Step 3

    Chemotherapy administration - CAPOX option

    Capecitabine will be taken by mouth

    Oxaliplatin will be administered through intravenous infusion

  4. Step 4

    Chemotherapy administration - FOLFOX option

    Fluorouracil will be administered through intravenous infusion

    Calcium folinate will be administered through intravenous infusion

    Oxaliplatin will be administered through intravenous infusion

  5. Step 5

    Follow-up period

    Regular blood samples will be collected to monitor ctDNA levels

    Your overall health status and quality of life will be assessed

    Imaging tests will be performed to monitor for any disease recurrence

    The study will continue until September 2030

Who can join the trial?

11 criteria

  • Must be 18 years or older
  • Must have a WHO performance score of 0-1 (ability to perform daily activities with minimal limitations)
  • Must provide signed informed consent for participation in the PLCRC study, including agreement for additional blood samples and future research
  • Must provide separate informed consent for the REACT trial
  • Must have confirmed rectal cancer through tissue examination, with either:
    • Previous treatment with radiation therapy (with or without chemotherapy), or
    • Cancer that has grown through the bowel wall (T4), or
    • Cancer that has spread to lymph nodes (N+)
    • Must be considered suitable by their doctor to receive combination chemotherapy treatment (either CAPOX or FOLFOX regimens)
    • Must be able to understand and read the Dutch language
    • Must have detectable circulating tumor DNA (ctDNA) in blood sample taken after surgery
    • Must be mentally capable of understanding and following study procedures

Who cannot join the trial?

14 criteria

  • History of other cancers within the past 5 years (except for adequately treated non-melanoma skin cancer or carcinoma in situ of the cervix)
  • Previous treatment with chemotherapy (treatment using drugs to destroy cancer cells) for rectal cancer
  • Serious heart conditions including heart failure (when heart cannot pump blood effectively) or recent heart attack within 6 months
  • Severe kidney or liver disease that could affect treatment
  • Active infection requiring systemic treatment (medication that affects the whole body)
  • Pregnant or breastfeeding women
  • Known allergic reactions to the study medications
  • Participation in another clinical trial within the past 30 days
  • Mental conditions that could interfere with following study procedures
  • Inability to give informed consent
  • Metastatic disease (cancer that has spread to other parts of the body)
  • Blood disorders that could make chemotherapy unsafe
  • Uncontrolled diabetes (high blood sugar levels)
  • Major surgery planned during the study period (except for the planned cancer surgery)
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.

We usually reply within a few days

Verified sites

All sites with verified contact details – recruitment status may not be available; ask directly

Trial locations

Where you can join this trial

Countries are shaded by recruitment status. Click a recruiting country to ask about joining there.

Recruiting
Not finding your country?

Not sure what to do next?

Joining a clinical trial can seem overwhelming. We guide you step by step, so you know exactly what to expect and how we support you through the process.

See the full process and FAQ

Investigated drugs

Based on the provided trial information, which focuses on adjuvant chemotherapy in rectal cancer patients, the typical medications used would be: FOLFOX is a combination chemotherapy treatment that includes multiple medications working together to kill cancer cells. It's commonly used as adjuvant therapy after surgery in rectal cancer patients. Capecitabine is an oral chemotherapy medication that turns into 5-fluorouracil in the body. It works by interfering with cancer cell growth and is often used as adjuvant therapy in rectal cancer treatment. 5-Fluorouracil (also known as 5-FU) is a chemotherapy medication that stops cancer cells from making DNA and RNA, which they need to grow and multiply. It's a standard treatment option in rectal cancer therapy. Note: While specific medications aren't explicitly listed in the source data, these are the standard adjuvant chemotherapy options typically used in rectal cancer treatment when ctDNA (circulating tumor DNA) is detected after surgery.

What is already known about the treatment

Based on the provided data, this appears to be a clinical trial studying adjuvant chemotherapy in rectal cancer, but specific medications are not listed in the source data. Without explicit medication names, I cannot create the requested medication descriptions. To properly describe specific medications, I would need information about which chemotherapy agents are being used in this trial. The data only indicates it's an adjuvant chemotherapy trial for rectal cancer patients with detectable ctDNA after surgery, but doesn't specify the medications involved. If you can provide the specific chemotherapy medications being used in this trial, I would be happy to create descriptions following the requested format: Medication Name – description...

Investigated diseases

Rectal Cancer - A disease that begins when cells in the rectum (the last part of the large intestine) start to grow out of control. It typically develops slowly from polyps, which are small growths on the inner lining of the rectum. The disease usually affects the innermost layer of the rectum first, and over time can grow through the rectal wall. Rectal cancer can spread to nearby tissues and lymph nodes, and may eventually reach other parts of the body. The condition often develops without early warning signs, though it may cause changes in bowel habits and rectal bleeding as it progresses.
Trial detailsLast updated 7 Oct 2026
Age18+ yearsPhasePhase IIITrial ID2024-517700-12-00Estimated enrolment103 patientsSponsorErasmus Universitair Medisch Centrum Rotterdam (Erasmus MC)

sourced from the EU Clinical Trials Register and site verification

Want to learn more about this trial or check if you can participate?

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.